This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

VX-745

EIP Pharma, LLC

Drug Names(s): VX-745

Description: VX-745 specifically inhibits the intra-cellular enzyme p38 mitogen activated protein kinase alpha (MAPK alpha).

Deal Structure: In a collaboration with Kissei that began in 1997, Vertex is pioneering the discovery and development of novel p38 MAP kinase inhibitors. Under the agreement, Vertex holds the development and commercial rights in the United States and Europe for its p38 MAP kinase inhibitors. Kissei holds development and commercial rights in Japan and certain Asian countries for VX-745.

In 2012, VX-745 was licensed by EIP Pharma for development in central nervous system (CNS) disorders from Vertex Pharmaceuticals.

Partners: Vertex Pharmaceuticals Incorporated


VX-745 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug